Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2019-02-20 Earnings Release
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Information sur chiffre d’affaires annuel
Earnings Release Classification · 98% confidence The document is titled "Theradiag annonce son chiffre d'affaires annuel 2018 ainsi que son niveau de trésorerie à fin 2018" (Theradiag announces its 2018 annual revenue and cash position at the end of 2018). It provides key financial figures for the full year 2018 (revenue and cash) and explicitly states that the full annual results will be released on March 27, 2019. This document serves as an early release of key performance indicators (KPIs) before the comprehensive annual report (10-K equivalent) or the detailed management discussion and analysis (MDA). Since it focuses on preliminary, high-level financial results for a period (annual), it fits the definition of an Earnings Release (ER). It is not the full Annual Report (10-K) because it explicitly points to a future date for the full results, and it is not a Call Transcript (CT) or Investor Presentation (IP). FY 2018
2019-02-20 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 89% confidence The document is titled "Agenda financier 2019" (Financial Agenda 2019) and lists future dates for key financial events such as revenue releases, annual results, and the General Assembly (AGM). This document is an announcement detailing the schedule of future corporate events and publications, rather than being one of the reports itself (like 10-K or IR). Since it announces the schedule for various corporate disclosures, including the AGM and financial results, it functions as a general corporate update regarding future reporting timelines. It does not fit perfectly into a specific report type (like ER or IR) because it is only the schedule. Given the options, this type of forward-looking schedule announcement, especially one that includes the AGM date, is best classified as a general regulatory announcement or a specific type of corporate update. Since it explicitly lists the date for the 'Assemblée Générale' (AGM), it is closely related to AGM information, but it is the *agenda*, not the meeting materials (AGM-R) or the proxy materials (PSI). It is a communication about future corporate events. The closest fit among the specific codes that deal with scheduled events or announcements is often the general regulatory filing category (RNS) or potentially a specific announcement type if one existed. However, since it is a press release detailing the schedule for future financial and corporate events, it is a general announcement. Given the options, and recognizing it is a press release announcing future dates, it is most appropriately categorized as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a report, which it is not—it's announcing the *date* of publication. RNS serves as the best general fallback for corporate announcements that don't fit elsewhere. I will assign RNS as the most appropriate general announcement category.
2019-02-14 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated January 15, 2019, announcing that THERADIAG obtained the CE mark for its Cosentyx® monitoring kit. It discusses product development, market position, and provides company background, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is a specific announcement regarding a regulatory/product milestone (CE mark) that doesn't fit the other specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend Notice (DIV). Since it is a general announcement of a significant business/product event that doesn't fit the more specific categories, the most appropriate fallback is Regulatory Filings (RNS), as it functions as a general regulatory/business update release.
2019-01-15 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated January 15, 2019, announcing that THERADIAG obtained the CE marking for a new monitoring test (Cosentyx®) for its LISA TRACKER® range. It discusses product development, market position, and provides contact information for investors and press. This type of announcement, which is a specific operational/product update rather than a mandatory periodic financial filing (like 10-K or IR) or a general regulatory filing (RNS), fits best under the category of general corporate news or investor relations material. Since it is not a formal earnings release (ER), management discussion (MDA), or a specific financing event (CAP), and it is not a presentation (IP) or a transcript (CT), it is best classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard corporate announcements, or potentially a type of Investor Relations update. Given the options, RNS serves as the most appropriate fallback for a significant, non-periodic corporate announcement that doesn't fit the other specific categories like DIV, DIRS, or ER. It is not a report itself, so RPA is unlikely unless it was announcing the publication of a larger report, which it is not.
2019-01-15 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Earnings Release Classification · 99% confidence The document is titled "Communiqué de Presse" (Press Release) and announces the annual balance of a liquidity contract ('Bilan annuel du contrat de liquidité') between Theradiag and Kepler Cheuvreux as of December 31, 2018. It details the number of shares and other instruments held in the liquidity account. This type of announcement, which reports on specific financial/contractual activities outside of standard periodic financial reports (like 10-K or IR), does not fit perfectly into the main categories (10-K, ER, IR, DIV, etc.). It is a specific regulatory or contractual disclosure. Since it is a press release detailing a specific financial arrangement update (liquidity contract balance), and it is not a general regulatory filing (RNS) or a report itself, it most closely aligns with a specific financial update. However, given the options, it is a specific announcement regarding the company's financial structure/arrangements. It is not a dividend (DIV), capital change (CAP/SHA), or insider trade (DIRS). It is a specific update on a financial arrangement. Since it is a press release announcing a specific financial status update, and it is not a standard regulatory filing like a 10-K or IR, the most appropriate general category for specific, non-standard announcements is often RNS (Regulatory Filings) if no better fit exists. However, the content is highly specific to a liquidity agreement, which is a form of capital management/financing activity. Given the limited options, and recognizing this is a specific contractual update announced via press release, it is best classified as a general Regulatory Filing (RNS) as it doesn't match the specific financial report types, or potentially CAP if viewed as a financing mechanism update. Given the nature of liquidity contract reporting, RNS is the safest fallback for specific, non-core reporting announcements. FY 2018
2019-01-08 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement dated January 3, 2019, titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French commercial code and AMF (Autorité des Marchés Financiers) regulations, presenting a table showing the total number of shares and voting rights as of December 31, 2018. This content directly relates to changes in the company's capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA). Although it is a formal regulatory disclosure, SHA is more specific than the general 'RNS' fallback. The document is short and presents definitive data, not an announcement *about* a report.
2019-01-03 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.